{"name":"Bio-Thera Solutions","slug":"bio-thera-solutions","ticker":"","exchange":"","domain":"biotherasolutions.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-02","label":"AVZIVI Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"AVZIVI Phase 3 readout (Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-31","label":"AVZIVI Phase 3 readout (Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"AVZIVI Phase 3 readout (Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-15","label":"AVZIVI Phase 2 readout (Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-01-01","label":"AVZIVI Phase 3 readout (Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-07-01","label":"AVZIVI Phase 3 readout (Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-10","label":"AVZIVI Phase 3 readout (Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-02-28","label":"AVZIVI Phase 3 readout (Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-12-31","label":"AVZIVI Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma)","drug":"AVZIVI","drugSlug":"bevacizumab-tnjn","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"BAT1406","genericName":"BAT1406","slug":"bat1406","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BAT2206","genericName":"BAT2206","slug":"bat2206","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"BAT2306","genericName":"BAT2306","slug":"bat2306","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"BAT2506 injection","genericName":"BAT2506 injection","slug":"bat2506-injection","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"BAT3306","genericName":"BAT3306","slug":"bat3306","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"BAT4406F Injection","genericName":"BAT4406F Injection","slug":"bat4406f-injection","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"BAT8001 for injection","genericName":"BAT8001 for injection","slug":"bat8001-for-injection","indication":"Solid tumors (specific indications under investigation in phase 3 trials)","status":"phase_3"},{"name":"BAT1706","genericName":"BAT1706","slug":"bat1706","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BAT1806","genericName":"BAT1806","slug":"bat1806","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BAT5906 injection","genericName":"BAT5906 injection","slug":"bat5906-injection","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"EU Avastin®","genericName":"EU Avastin®","slug":"eu-avastin","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"Paclitaxel for Injection","genericName":"Paclitaxel for Injection","slug":"paclitaxel-for-injection","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"US-Keytruda®","genericName":"US-Keytruda®","slug":"us-keytruda","indication":"Metastatic melanoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"BAT1006","genericName":"BAT1006","slug":"bat1006","indication":"Other","status":"phase_1"},{"name":"BAT8001","genericName":"BAT8001","slug":"bat8001","indication":"Other","status":"phase_1"},{"name":"AVZIVI","genericName":"BEVACIZUMAB-TNJN","slug":"bevacizumab-tnjn","indication":"Other","status":"marketed"},{"name":"BAT2022","genericName":"BAT2022","slug":"bat2022","indication":"Other","status":"phase_1"},{"name":"QLETLI","genericName":"QLETLI","slug":"qletli","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Stelara (EU-sourced)","genericName":"Stelara (EU-sourced)","slug":"stelara-eu-sourced","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Actemra(EU-licensed)","genericName":"Actemra(EU-licensed)","slug":"actemra-eu-licensed","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"EU Simponi","genericName":"EU Simponi","slug":"eu-simponi","indication":"Rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"BAT1406","genericName":"BAT1406","slug":"bat1406","phase":"phase_3","mechanism":"BAT1406 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"BAT2206","genericName":"BAT2206","slug":"bat2206","phase":"phase_3","mechanism":"BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Stelara (EU-sourced)","genericName":"Stelara (EU-sourced)","slug":"stelara-eu-sourced","phase":"phase_3","mechanism":"Stelara is a human monoclonal antibody that blocks the IL-12 and IL-23 cytokines to suppress immune-mediated inflammation.","indications":["Moderate to severe plaque psoriasis","Active Crohn's disease","Active ulcerative colitis","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"BAT1006","genericName":"BAT1006","slug":"bat1006","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BAT2306","genericName":"BAT2306","slug":"bat2306","phase":"phase_3","mechanism":"BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"BAT2506 injection","genericName":"BAT2506 injection","slug":"bat2506-injection","phase":"phase_3","mechanism":"BAT2506 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"BAT3306","genericName":"BAT3306","slug":"bat3306","phase":"phase_3","mechanism":"BAT3306 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"BAT4406F Injection","genericName":"BAT4406F Injection","slug":"bat4406f-injection","phase":"phase_2","mechanism":"BAT4406F Injection is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BAT8001","genericName":"BAT8001","slug":"bat8001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BAT8001 for injection","genericName":"BAT8001 for injection","slug":"bat8001-for-injection","phase":"phase_3","mechanism":"BAT8001 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.","indications":["Solid tumors (specific indications under investigation in phase 3 trials)"],"catalyst":""},{"name":"AVZIVI","genericName":"BEVACIZUMAB-TNJN","slug":"bevacizumab-tnjn","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Actemra(EU-licensed)","genericName":"Actemra(EU-licensed)","slug":"actemra-eu-licensed","phase":"phase_3","mechanism":"Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses.","indications":["Rheumatoid arthritis","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease"],"catalyst":""},{"name":"BAT1706","genericName":"BAT1706","slug":"bat1706","phase":"phase_3","mechanism":"BAT1706 is a bispecific antibody that simultaneously engages PD-1 on T cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"BAT1806","genericName":"BAT1806","slug":"bat1806","phase":"phase_3","mechanism":"BAT1806 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"BAT2022","genericName":"BAT2022","slug":"bat2022","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BAT5906 injection","genericName":"BAT5906 injection","slug":"bat5906-injection","phase":"phase_3","mechanism":"BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"EU Avastin®","genericName":"EU Avastin®","slug":"eu-avastin","phase":"phase_3","mechanism":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with chemotherapy)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""},{"name":"EU Simponi","genericName":"EU Simponi","slug":"eu-simponi","phase":"phase_3","mechanism":"Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Paclitaxel for Injection","genericName":"Paclitaxel for Injection","slug":"paclitaxel-for-injection","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Other solid tumors (in development or approved use)"],"catalyst":""},{"name":"QLETLI","genericName":"QLETLI","slug":"qletli","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-Keytruda®","genericName":"US-Keytruda®","slug":"us-keytruda","phase":"phase_3","mechanism":"US-Keytruda is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Metastatic melanoma","Non-small cell lung cancer","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNaThWWUhGOG05MGx4N3p0aFQ3MnBwR0FYcHY1WFdiYlVIZDBFWmJYNnE3eGk5UkRUM0hzbmdOZnMwbi1fQ3ZxQzJGOWQwcy1UM0lmUmwzdm5ZVU91SkpnT09oWDAtVzdBa2MtN2FoR21PSmY2bkFJNlQ4MWxteGowQ2NqU3UzTVU5UEZYeUx2RXhFMHNC?oc=5","date":"2026-04-03","type":"deal","source":"AASTOCKS.com","summary":"Sihuan Pharmaceutical (00460.HK) and Bio-Thera Solutions (02315.HK) Form Strategic Partnership - AASTOCKS.com","headline":"Sihuan Pharmaceutical (00460.HK) and Bio-Thera Solutions (02315.HK) Form Strategic Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPdjdqRi1QWFA3eWlQOS1Td3lXRXIzN3NGalN0NExGdGtWZld6QlRvWERJOWRqUG5OUzF5WnlIZXFxREhuN2kwMUR0anNHZ0dNc0RpOFNJZEdla3Y5WWg1ZndSZjFwUFNrXzFyY21yM3lRUklldlB2Y0sxa3V3UE9yZnNDOFc1ZEVScmFLajh4eUppT21ON1JEeDVn?oc=5","date":"2026-04-01","type":"deal","source":"AASTOCKS.com","summary":"Sihuan Pharmaceutical (00460.HK) and Bio-Thera Solutions (02315.HK) Form Strategic Partnership - AASTOCKS.com","headline":"Sihuan Pharmaceutical (00460.HK) and Bio-Thera Solutions (02315.HK) Form Strategic Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijANBVV95cUxPMGtoUTJkTjlTWlh5ajRWNm5nUENvVF9nWUE2T1pOUnNkalIyelVqZFhBSTJYS1ZlTUxlS2JWOTJUNjBjMWZFamVIazByVFNZNDljdEltbHVDSk9lQWhEbUF3ODJrb0U5VGF0VnhpdkJGU0RGbGs0MjRnSDBxcktYblJsNHpjdTJZSWs0d3Y5dUtNcGQ2cVY5T2dYODBHa3VTUUsyMzF5X3hMUTd0TDhrSnVVSWQtdXp4UktQU3E5UWxiWE5WMjdKb0RyMWRPWGVxZzVYNkpMNjlaOVZFbjBFdTZpVHNSRmhhTGxac2RMYXZJUEJPRXNodTJOaEZpR3lYMkJVS0VUM1JxbDhoTmNpY0pVY0haNHd4M0h6ZjNWaEtKNGo5dzBBWE1IaXdJU1U5N1JxV0tqdGEtSl9ST21UWXBWZG5FeUJaaWFBQUNxdldOUGxlZ0NpWGMzS2xRbl9pZnc1NEkwbUNOMnZoMVhDODN2bXlWTTdqZl9oUXA5TzBZakVaRzNUSFNNMEI?oc=5","date":"2026-03-23","type":"deal","source":"PR Newswire","summary":"Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and L","headline":"Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVXZQVHBhZFpNa1k1Y2NVVWhQVW8ydG9pUWYtVHNwTC0tR0kzWXRxa0xvbldFekx6VWl1RG5jVW1MZTRhUGkwa0x4cWlQemlDYWEwM295UFhOcXl1Mkg0b3Y0cU14ak9JTXlUVzYwUUs5S2lGZGNzNVN1aHdHNTZOU1JqdEIxdXdHX2doTU5WNkIzRUFUc1J2Tmk1a3FZVFBwa1JfWA?oc=5","date":"2026-02-13","type":"patent","source":"The Pharma Letter","summary":"STADA and Bio-Thera win EC nod for Simponi biosimilar - The Pharma Letter","headline":"STADA and Bio-Thera win EC nod for Simponi biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNanF5Y3lDUnRTLVhKR3hUMW4wNmVEbzQ0eDRWdk1lcW5uRkJ6czBKNjlPMW4zd2pjNnZnWXo1V3ozSlJkMDRVQnhrV1RqU01yckJRaUxUZnpCTm81ZkZGUngxcXR4Y3ZqaG5nV1RuNWpKaDZCbjVMeVZQREN2UHRYLXVQdE9PWFhhZmlIc3B5YjFIb21DZ0xvWW9SdjB2MG50Sm5N?oc=5","date":"2026-02-13","type":"patent","source":"Contract Pharma","summary":"STADA, Bio-Thera Win EU Clearance for Simponi Biosimilar - Contract Pharma","headline":"STADA, Bio-Thera Win EU Clearance for Simponi Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQSDRKbzZYMmJKWEpoMllzSnNRXzVXOGlhU2pRUlhhMmxsSVh2Skk4VTN6eE5nVGs3TTlxWmd3RHB6OWUtSjhPQ25DWE9CU0JEZE9HRktTNkNlbEtjOHVfeDFzZVhaRkgxVFNRa3loaktSMzFYaHJhTXlOVy1jNV9fOUJLamczekhZYjN4U2xWb2RUSlFrZ19vV3Q0ZGpMVWVDMEtjYW84aDNQR2pUZFd2bEhkbGNSdklleDBkN2tBVzB6WnVrbFFkLVZ5bFYzXzh3a2dyNGh0QkhrUHZZbWtGclZpSm1UUzIz?oc=5","date":"2026-02-13","type":"patent","source":"PR Newswire","summary":"STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - PR Newswire","headline":"STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSWFxZVBUV1pmdGdqbjVtZjMzNnlTTzBuUng1NHVnZ2dZdm52aDJDZ1BCR2tidzM2c2ZRTDFHRzcydng4RW91eWJjMmdSS2pxWVozVzBSaTFQZUVaWlhBbElkN1UwZlNHb3JleHlMVE5tSjlEcDkwa1NMcVRRMm9NeUEwRmVzOE8taGZCeG81UkdyRjZBVzNTN0dsWXpJWTZjZDBvZEdRdkZteG1vNXNoTFdIWW0?oc=5","date":"2026-02-09","type":"deal","source":"The Pharma Letter","summary":"Bio-Thera, Avalon strike MENA deal for proposed Keytruda biosimilar - The Pharma Letter","headline":"Bio-Thera, Avalon strike MENA deal for proposed Keytruda biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZjhVckNSWl81NXNqRURiQmtFR09EVXF4Z25SbTgzRVBFaWJOUk42aG9JUXUyZ2JpNGh2YzVCakpuV0VCYkJ5UkZYZDkxSWdEWks5bXR1VTNDaTB5VmZmMWZvSmF3UUdsVmdTejNPejBCYVZGYWNLeDRXWmdLb2hTdDhZNUZDMkNic0VCUWZSUFJtYU04bDVMZEltc1VYRGljSHd3R0dBZWx2UQ?oc=5","date":"2025-10-09","type":"deal","source":"Contract Pharma","summary":"Bio-Thera Solutions & Intas Pharmaceuticals Expand Partnership - Contract Pharma","headline":"Bio-Thera Solutions & Intas Pharmaceuticals Expand Partnership","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-09","type":"deal","source":"PR Newswire","summary":"Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License A","headline":"Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Ref","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPS1JWczMxeWFqZ0JCS2lMT1pRV2o4WUZOQ0RmOWtWRndWckdtaUZUWklSZFU5WWNIWUNOekVIYmIta20yUEgtbGg2UzVaRGVSTXBFamNEbzRaajA3TkN0Yk50a2ZkTjNaOG91aEpuUF9yZWJ1RTVib09ULTZHN2JCc1haYlNnUUVzd05DY3FVcmpYMEgtbndqVl8tVUI4WjAySXpUUDlDWQ?oc=5","date":"2025-08-22","type":"patent","source":"Contract Pharma","summary":"Bio-Thera, STADA Extend Biosimilars Alliance to Tocilizumab - Contract Pharma","headline":"Bio-Thera, STADA Extend Biosimilars Alliance to Tocilizumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQRHc5RmhzX3d2ZVBCX1dFMndVdHhBaUI3Z2xjdzF2ZHdVd05WcXlsemRvV29kbms5RTVVLXpmU0ExdnB3VklPNzBvZnhJOUtVdE5ycWlYblk5SjNkTVItNTIyRVExX2dScW1NZV9HODd4WGp0eHFJVURiN1dncURWVkhDQ2IwdFFkc1AwVUpyRmZGRjZXbldvOFBveUVaRzdNd3ZCOVE4YmhPWERyRXFQdHczRmZvNU5jWDN4dlFRTEVMUVB3ZFVpNFBIeWg1ejZ3bFRVRTE2N0c?oc=5","date":"2025-08-21","type":"deal","source":"Reuters","summary":"China's Bio-Thera Solutions licenses its arthritis drug to Germany's STADA - Reuters","headline":"China's Bio-Thera Solutions licenses its arthritis drug to Germany's STADA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPQ0JvQXhWa3hjUTh4MkhQZUczUWN3RXRmUmpsTVZDR2JSM2dFOTFqQWZMVVNzYWR5cEtkazV3emI2dkhjOGJVeHdzdFFDeDlYbVdXUEFUdnBjbHJVdjJLZDNROXllYWcwRzcwUGZOeWpYTklfbnNMMVczV19PTThBNkhTaVM2cGw0bngxd2owX1VkZkpBTUNQaHZPMlMzSGZlTmdSNVpQUTRQbHF5RDJzQU1kRnViX2ZCc2ZXazNZTEpGRkU3QV9weEN1R2tJZGdSYXhWRUpjQmw3Q3RxYUk4dUpYY1g0ZzhRNGtrU3VCNDdQa1RLRkZrclNUcld0RFZwb3c?oc=5","date":"2025-07-16","type":"regulatory","source":"PR Newswire","summary":"Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi® - PR Newswire","headline":"Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi®","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"phase_3":15,"phase_1":3,"phase_2":1,"marketed":2},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}